Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.28 USD
Change Today +0.04 / 3.23%
Volume 184.8K
BPTH On Other Exchanges
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

bio-path holdings inc (BPTH) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/3/14 - $3.02
52 Week Low
05/12/15 - $0.99
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIO-PATH HOLDINGS INC (BPTH)

Related News

No related news articles were found.

bio-path holdings inc (BPTH) Related Businessweek News

No Related Businessweek News Found

bio-path holdings inc (BPTH) Details

Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion in the United States. Its principal product is Liposomal Grb-2, which is in a Phase II study for blood cancers, as well as in preclinical studies for triple negative and inflammatory breast cancers. The company is also developing Liposomal Bcl-2, which is a liposome delivered antisense cancer drug for treating lymphoma, breast cancer, colon cancer, prostate cancer, and leukemia. It has license agreement with MD Anderson Cancer Center relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

8 Employees
Last Reported Date: 03/16/15
Founded in 2007

bio-path holdings inc (BPTH) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $525.0K
Co-Founder and Director
Total Annual Compensation: $52.0K
Chief Operating Officer and Secretary
Total Annual Compensation: $190.0K
Compensation as of Fiscal Year 2014.

bio-path holdings inc (BPTH) Key Developments

Bio-Path Holdings, Inc.(NasdaqCM:BPTH) dropped from Russell 2000 Index

Bio-Path Holdings, Inc. will be removed from Russell 2000 Index

Bio-Path Holdings, Inc.(NasdaqCM:BPTH) dropped from Russell 3000 Index

Bio-Path Holdings, Inc. will be removed from Russell 3000 Index.

Bio-Path Holdings, Inc. Announces Earnings Results for the First Quarter Ended March 31, 2015; Provides Update on Phase 2 Combination Trial

Bio-Path Holdings, Inc. announced earnings results for the first quarter ended March 31, 2015. The Company reported a net loss of $1.4 million for the three months ended March 31, 2015, compared to a net loss of $0.5 million for the three months ended March 31, 2014. The increase was due to higher professional fees, increased preclinical activity, manufacturing development expenses and personnel costs. The Company reported a net loss per share of $0.02 for the three months ended March 31, 2015, based on 89,762,872 weighted average shares outstanding, compared to a net loss of $0.01 per share for the same period in 2014. Net cash used in operating activities for the three months ended March 31, 2015 was $1.4 million compared to $0.5 million for the comparable period in 2014. Enrollment continues into the safety portion of the Phase 2 combination trial evaluating Liposomal Grb-2 and low dose Ara-C frontline therapy in patients with acute myeloid leukemia (AML). The safety portion of the Phase 2 trial is designed to assess two cohorts: 60 mg/m2 of Liposomal Grb-2 and frontline Ara-C and 90 mg/m2 of Liposomal Grb-2 and frontline Ara-C in its intended use in combination with an existing chemotherapeutic agent. Bio-Path received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its lead compound Liposomal Grb-2 for the treatment of AML. Orphan drug status provides Bio-Path with seven years of exclusivity after receiving formal marketing approval, as well as additional development incentives. Preclinical testing of its lead product candidate, Liposomal Grb-2, is continuing, into two additional indications: triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates. The Company is working in collaboration with a leading researcher working in the MD Anderson breast cancer program. The Company expects to complete the final in vivo segment of the preclinical program in 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BPTH:US $1.28 USD +0.04

BPTH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BPTH.
View Industry Companies

Industry Analysis


Industry Average

Valuation BPTH Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 8.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-PATH HOLDINGS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at